Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation

Pharmacogenetics and Genomics

Volumn 24, Issue 9, 2014, Pages 427-435

  Tapirdamaz, Özlem ^a   Hesselink, Dennis A ^a   El Bouazzaoui, Samira ^a   Azimpour, Mohammad ^a   Hansen, Bettina ^a   Van Der Laan, Luc J W ^a   Polak, Wojciech G ^a   Kwekkeboom, Jaap ^a   Van Schaik, Ron H N ^a   Van Gelder, Teun ^a   Metselaar, Herold J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ABCB1; chronic kidney disease; cytochrome P450; liver transplantation; pharmacogenetics; tacrolimus

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A5; DNA; IMMUNOSUPPRESSIVE AGENT; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; ABC TRANSPORTER A1; ABCA1 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ADULT; ARTICLE; CAUCASIAN; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; NEPHROTOXICITY; NETHERLANDS; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; DOSE CALCULATION; GENETIC ASSOCIATION; GENETICS; GRAFT REJECTION; LIVING DONOR; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC;

ADULT; ATP BINDING CASSETTE TRANSPORTER 1; CALCINEURIN INHIBITORS; CYTOCHROME P-450 CYP3A; DRUG DOSAGE CALCULATIONS; FEMALE; GENETIC ASSOCIATION STUDIES; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RENAL INSUFFICIENCY, CHRONIC; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 84906087632     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0000000000000063     Document Type: Article

References (47)

1. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs 2001; 61:1957-2016
2. Spencer CM, Goa KL, Gillis JC. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54:925-975
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43:623-653
4. Quteineh L, Verstuyft C, Furlan V, Durrbach A, Letierce A, Ferlicot S, et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin Pharmacol Toxicol 2008; 103:546-552
5. Hall SD, Thummel KE, Watkins PB, Lown KS, Benet LZ, Paine MF, et al. Molecular and physical mechanisms of first-pass extraction. Drug Metab Dispos 1999; 27:161-166
6. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40:159-168
7. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080
8. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporinemetabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43:630-635
9. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989; 36:97-105
10. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, Watkins PB. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994; 22:947-955
11. Jounaidi Y, Hyrailles V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant: A candidate for the polymorphic expression of the protein?. Biochem Biophys Res Commun 1996; 221:466-470
12. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391
13. Hesselink DA, Bouamar R, Elens L, Van Schaik RH, Van Gelder T. The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation. Clin Pharmacokinet 2014; 53:123-139
14. Hesselink DA, Van Gelder T, Van Schaik RH. The pharmacogenetics of calcineurin inhibitors: One step closer toward individualized immunosuppression?. Pharmacogenomics 2005; 6:323-337
15. Kuypers DR, Naesens M, De Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-Associated nephrotoxicity in renal allograft recipients. Ther Drug Monit 2010; 32:394-404
16. Vafadari R, Bouamar R, Hesselink DA, Kraaijeveld R, Van Schaik RH, Weimar W, et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther Drug Monit 2013; 35:459-465
17. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478
18. Hesselink DA, Bouamar R, Van Gelder T. The pharmacogenetics of calcineurin inhibitor-related nephrotoxicity. Ther Drug Monit 2010; 32:387-393
19. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16:1501-1511
20. Naesens M, Lerut E, Sarwal M, Van Damme B, Vanrenterghem Y, Kuypers DR. Balancing efficacy and toxicity of kidney transplant immunosuppression. Transplant Proc 2009; 41:3393-3395
21. Kuypers DR, Naesens M, De Jonge H, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-Term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin Pharmacol Ther 2007; 82:711-725
22. Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-To-dose ratio in renal transplant recipients. Transplantation 2003; 76:1233-1235
23. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, et al. Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-Term follow-up. Clin Pharmacol Ther 2010; 88:95-100
24. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13:661-674
25. Hawwa AF, McKiernan PJ, Shields M, Millership JS, Collier PS, McElnay JC. Influence of ABCB1 polymorphisms and haplotypes on tacrolimus nephrotoxicity and dosage requirements in children with liver transplant. Br J Clin Pharmacol 2009; 68:413-421
26. Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008; 18:413-423
27. Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005; 16:763-773
28. Hesse CJ, Baan CC, Balk AH, Metselaar HJ, Weimar W, Van Gelder T. Evaluation of the new EMIT enzyme immunoassay for the determination of whole-blood tacrolimus concentrations in kidney, heart, and liver transplant recipients. Transplant Proc 2002; 34:2988-2990
29. Hesselink DA, Van Schaik RH, Van Der Heiden IP, Van Der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-254
30. Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349:931-940
31. ORiordan A, Wong V, McCormick PA, Hegarty JE, Watson AJ. Chronic kidney disease post-liver transplantation. Nephrol Dial Transplant 2006; 21:2630-2636
32. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, et al. Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74:1486-1489
33. Van Schaik RH, Van Der Heiden IP, Van Den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48:1668-1671
34. Goto M, Masuda S, Kiuchi T, Ogura Y, Oike F, Okuda M, et al. CYP3A5. *1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 2004; 14:471-478
35. Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, Israni A. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant 2012; 12:3326-3336
36. Kreutz R, Bolbrinker J, Van Der Sman-de Beer F, Boeschoten EW, Dekker FW, Kain S, et al. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-Term treatment with cyclosporine. Pharmacogenomics J 2008; 8:416-422
37. Gervasini G, Garcia M, Macias RM, Cubero JJ, Caravaca F, Benitez J. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int 2012; 25:471-480
38. Moore J, McKnight AJ, Döhler B, Simmonds MJ, Courtney AE, Brand OJ, et al. Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol 2012; 23:1891-1899
39. Snanoudj R, Royal V, Elie C, Rabant M, Girardin C, Morelon E, et al. Specificity of histological markers of long-Term CNI nephrotoxicity in kidney-Transplant recipients under low-dose cyclosporine therapy. Am J Transplant 2011; 11:2635-2646
40. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, Rodriguez RA, OHare AM. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167:1271-1276
41. Noll BD, Coller JK, Somogyi AA, Morris RG, Russ GR, Hesselink DA, et al. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies. Ther Drug Monit 2013; 35:617-623
42. Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, et al. Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition. Clin Pharmacol Ther 2012; 92:737-745
43. Klauke B, Wirth A, Zittermann A, Bohms B, Tenderich G, Körfer R, Milting H. No association between single nucleotide polymorphisms and the development of nephrotoxicity after orthotopic heart transplantation. J Heart Lung Transplant 2008; 27:741-745
44. Shuker N, Bouamar R, Weimar W, Van Schaik RH, Van Gelder T, Hesselink DA. ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. Clin Chim Acta 2012; 413 (17-18):1326-1337
45. Matas AJ. Chronic progressive calcineurin nephrotoxicity: An overstated concept. Am J Transplant 2011; 11:687-692
46. Matas AJ. Calcineurin inhibitors: Short-Term friend, long-Term foe?. Clin Pharmacol Ther 2011; 90:209-211
47. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. H2304 Study Group. Renal function at two years in liver transplant patients receiving everolimus: Results of a randomized, multicenter study. Am J Transplant 2013; 13:1734-1745